Head-to-head · Cost-Efficiency Index
Medro vs StackMD
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Medro
Shoppers who will commit to a longer plan to unlock Medro's lowest published tier.
Visit MedroStackMD
Shoppers price-scanning for the lowest advertised entry point, who should confirm true dose-adjusted cost before signing up.
Visit StackMDThe verdict
Medro and StackMD tie on the Cost-Efficiency Index at 60/100, so neither wins outright on the numbers. For most shoppers we'd start with Medro (ranked #253, a hair above #257) — Shoppers who will commit to a longer plan to unlock Medro's lowest published tier. But StackMD is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Medro.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Medro | StackMD |
|---|---|---|
| Cost-Efficiency Index | 60/100 | 60/100 |
| Semaglutide / mo | $199/mo (compounded) | Not disclosed |
| Tirzepatide / mo | $299/mo (compounded) | Not disclosed |
| Semaglutide / yr (modeled) | $2,388 | — |
| Tirzepatide / yr (modeled) | $3,588 | — |
| Coverage | All 50 states | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Compounded only |
| Rank here | #253 | #257 |
Medro
60/100Where the value is
- Live pricing tiers for both semaglutide and tirzepatide are transparent and fully disclosed (month-to-month through 12-month) without needing to enter the intake flow
- LegitScript-certified (seal #50716646, verified against legitscript.com) and available in all 50 states
- Named clinical partner (Arora Health & Aesthetics, LLC — Dr. Sean Arora, NPI 1841729449, Seattle, WA) and named compounding pharmacy (The Pharmacy Hub, Miami, FL) — both real, both verifiable, though neither is surfaced in the site's marketing copy
The tradeoffs
- The lowest advertised rate ($149 semaglutide / $224 tirzepatide) requires a full 12-month prepaid commitment; the no-commitment month-to-month rate is 33% higher ($199/$299)
- No mg dose is disclosed for any pricing tier — the plans are priced by commitment length only, so it's unclear what dose a given monthly price actually delivers
StackMD
60/100Where the value is
- Low advertised entry price ($99/mo) for both semaglutide and tirzepatide
- Clear FDA-compounding disclaimer shown up front
- Distinct national telehealth brand (separate from the similarly-named Long Island clinic)
The tradeoffs
- Identical $99 headline for both drugs strongly suggests a lowest-dose teaser, not full treatment pricing
- No dose tiers, medical director, pharmacy name, states list, or LegitScript status could be confirmed
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.